Resmed Completes Noctrix Health Acquisition to Expand Sleep Care
SAN DIEGO, June 1, 2026 Resmed has completed its acquisition of Noctrix Health, significantly expanding its clinical sleep health...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SAN DIEGO, June 1, 2026 Resmed has completed its acquisition of Noctrix Health, significantly expanding its clinical sleep health...
SOUTH SAN FRANCISCO, Calif., June 1, 2026 IDEAYA Biosciences and Servier have unveiled compelling results from the registrational Phase...
THOUSAND OAKS, Calif., June 1, 2026 Amgen has secured a major regulatory milestone with the European Commission approval of...
MOUNTAIN VIEW, Calif., May 29, 2026 NeuroPace, Inc., a leading medical technology company focused on transforming the treatment of...
MONTREAL, Canada, May 29, 2026 Leica Biosystems, a global leader in anatomic and digital pathology solutions, and CellCarta, a...
CHICAGO, Ill., May 29, 2026 Cardiosense has achieved a major regulatory milestone with the U.S. Food and Drug Administration...
MENLO PARK, Calif., May 27, 2026 Subtle Medical, a leading developer of AI-powered medical imaging software, has announced that...
AUSTIN, Texas, May 26, 2026 TOBY, Inc., a biotechnology company focused on non-invasive disease detection technologies, has announced that...
GALWAY, Ireland, May 20, 2026 Medtronic plc has announced its intent to acquire SPR Therapeutics, Inc. in a deal...
VANCOUVER, British Columbia, May 20, 2026 Optimi Health Corp. has announced the pricing of an oversubscribed US$15 million underwritten...
